Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
0.2793 x 5 0.2800 x 2
Post-market by (Cboe BZX)
0.2800 +0.0250 (+9.80%) 04/11/25 [NASDAQ]
0.2793 x 5 0.2800 x 2
Post-market 0.2793 -0.0007 (-0.25%) 17:15 ET
Quote Overview for Fri, Apr 11th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.2550
Day High
0.2996
Open 0.2790
Previous Close 0.2550 0.2550
Volume 414,400 414,400
Avg Vol 466,080 466,080
Stochastic %K 12.35% 12.35%
Weighted Alpha -82.20 -82.20
5-Day Change -0.0016 (-0.57%) -0.0016 (-0.57%)
52-Week Range 0.2425 - 3.4500 0.2425 - 3.4500
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,901
  • Shares Outstanding, K 71,075
  • Annual Sales, $ 570 K
  • Annual Income, $ -26,430 K
  • EBIT $ -62 M
  • EBITDA $ -61 M
  • 60-Month Beta 0.44
  • Price/Sales 32.02
  • Price/Cash Flow N/A
  • Price/Book 0.27
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.38
  • Most Recent Earnings $-0.13 on 03/11/25
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 615.51% ( -79.39%)
  • Historical Volatility 104.39%
  • IV Percentile 88%
  • IV Rank 62.45%
  • IV High 930.51% on 02/28/25
  • IV Low 91.73% on 05/10/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 935
  • Open Int (30-Day) 963

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 4
  • High Estimate -0.13
  • Low Estimate -0.15
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2425 +15.46%
on 04/09/25
Period Open: 0.4900
0.5500 -49.09%
on 03/13/25
-0.2100 (-42.86%)
since 03/11/25
3-Month
0.2425 +15.46%
on 04/09/25
Period Open: 0.8207
0.8765 -68.05%
on 01/13/25
-0.5407 (-65.88%)
since 01/10/25
52-Week
0.2425 +15.46%
on 04/09/25
Period Open: 3.2700
3.4500 -91.88%
on 04/30/24
-2.9900 (-91.44%)
since 04/11/24

Most Recent Stories

More News
Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

OVID : 0.2800 (+9.80%)
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

OVID : 0.2800 (+9.80%)
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

OVID : 0.2800 (+9.80%)
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

OVID : 0.2800 (+9.80%)
Ovid Therapeutics to Host Investor Event

OVID : 0.2800 (+9.80%)
3 'Strong Buy'-Rated Stocks to Buy Now on the Dip

These outstanding growth stocks are worth buying on the dip.

AMZN : 184.87 (+2.01%)
$SPX : 5,363.36 (+1.81%)
GEHC : 62.81 (+0.85%)
GD : 276.65 (+2.34%)
OVID : 0.2800 (+9.80%)
TAK : 13.88 (+0.07%)
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

Ovid executing on its strategy to build a leading epilepsy pipelineOV329 expected to enter the clinic in 2022Organization reshaped to reduce personnel by...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...

OVID : 0.2800 (+9.80%)
Healx and Ovid Therapeutics to Enter Strategic Partnership

– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other Indications – NEW YORK, N.Y. and...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results

Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its pipeline of...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics Appoints Dr. Kevin Fitzgerald to Board of Directors

NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...

OVID : 0.2800 (+9.80%)
Ovid Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with neurological...

OVID : 0.2800 (+9.80%)

Business Summary

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved...

See More

Key Turning Points

3rd Resistance Point 0.3460
2nd Resistance Point 0.3228
1st Resistance Point 0.3014
Last Price 0.2800
1st Support Level 0.2568
2nd Support Level 0.2336
3rd Support Level 0.2122

See More

52-Week High 3.4500
Fibonacci 61.8% 2.2247
Fibonacci 50% 1.8463
Fibonacci 38.2% 1.4678
Last Price 0.2800
52-Week Low 0.2425

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.